NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis

Nature

Volumn 531, Issue 7593, 2016, Pages 253-257

  Ma, Chi ^a   Kesarwala, Aparna H ^a   Eggert, Tobias ^a   Medina Echeverz, José ^a   Kleiner, David E ^a   Jin, Ping ^b   Stroncek, David F ^b   Terabe, Masaki ^a   Kapoor, Veena ^a   ElGindi, Mei ^a   Han, Miaojun ^a   Thornton, Angela M ^c   Zhang, Haibo ^a   Egger, Michle ^d   Luo, Ji ^a   Felsher, Dean W ^e   McVicar, Daniel W ^f   Weber, Achim ^d   Heikenwalder, Mathias ^g,h   Greten, Tim F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e STANFORD UNIVERSITY   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ARACHIDONIC ACID; CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE IA; CASPASE 3; CASPASE 7; CD69 ANTIGEN; DOCOSAHEXAENOIC ACID; HERMES ANTIGEN; INTERLEUKIN 17; LINOLEIC ACID; LIPOCORTIN 5; PADGEM PROTEIN; PALMITIC ACID; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REACTIVE OXYGEN METABOLITE; STEARIC ACID; UNCLASSIFIED DRUG; CHOLINE; METHIONINE;

CANCER; CARCINOGEN; CELLS AND CELL COMPONENTS; DISEASE INCIDENCE; IMMUNE RESPONSE; METABOLISM; OXIDATION; RODENT; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL DISRUPTION; CELL FUNCTION; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; JURKAT CELL LINE; LIPID ANALYSIS; LIPID COMPOSITION; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LYMPHOCYTE COUNT; MALE; METABOLIC INHIBITION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOLECULAR WEIGHT; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN DEPLETION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T-CELL LEUKEMIA CELL LINE; UPREGULATION; ANIMAL; C57BL MOUSE; CARCINOGENESIS; CASE CONTROL STUDY; DEFICIENCY; DIET; DISEASE MODEL; IMMUNOLOGY; LIVER; LIVER TUMOR; METABOLISM; ONCOGENE MYC; PATHOLOGY;

UNITED STATES;

ANIMALS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHOLINE; DIET; DISEASE MODELS, ANIMAL; GENES, MYC; HEPATOCYTES; HUMANS; LINOLEIC ACID; LIPID METABOLISM; LIVER; LIVER NEOPLASMS; MALE; METHIONINE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84961683188     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature16969     Document Type: Article

References (41)

1. European Association For The Study Of The Liver & European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56 908-943 (2012
2. Sun, B., & Karin, M. Obesity, inflammation, and liver cancer. J. Hepatol. 56, 704-713 (2012
3. Michelotti, G. A., Machado, M. V., & Diehl, A. M. NAFLD, NASH and liver cancer. Nature Rev. Gastroenterol. Hepatol. 10, 656-665 (2013
4. Schuppan, D., & Schattenberg, J. M. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J. Gastroenterol. Hepatol. 28 (suppl. 1), 68-76 (2013
5. Wree, A., Broderick, L., Canbay, A., Hoffman, H. M., & Feldstein, A. E. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nature Rev. Gastroenterol. Hepatol. 10, 627-636 (2013
6. Greten, T. F., Wang, X. W., & Korangy, F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut 64, 842-848 (2015
7. Greten, T. F., Duffy, A. G., & Korangy, F. Hepatocellular carcinoma from an immunologic perspective. Clin. Cancer Res. 19, 6678-6685 (2013
8. Wolf M. J., et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 26, 549-564 (2014
9. Shachaf C. M., et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431, 1112-1117 (2004
10. Rinella M. E., et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J. Lipid Res. 49, 1068-1076 (2008
11. Yang L., et al. Transforming growth factor β signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology 59, 483-495 (2014
12. Park E. J., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197-208 (2010
13. Kapanadze T., et al. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J. Hepatol. 59, 1007-1013 (2013
14. Xia S., et al. Gr-1+ CD11b+ myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity. J. Biol. Chem. 286, 23591-23599 (2011
15. Baeck C., et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1)diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61, 416-426 (2012
16. Henning J. R., et al. Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology 58, 589-602 (2013
17. Ma X., et al. A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology 46, 1519-1529 (2007
18. Rakhra K., et al. CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18, 485-498 (2010
19. Kang T. W., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479, 547-551 (2011
20. Kreiter S., et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692-696 (2015
21. Giesbertz P., et al. Metabolite profiling in plasma and tissues of ob/ob and db/db mice identifies novel markers of obesity and type 2 diabetes. Diabetologia 58, 2133-2143 (2015
22. Schönfeld, P., & Wojtczak, L. Fatty acids as modulators of the cellular production of reactive oxygen species. Free Radic. Biol. Med. 45, 231-241 (2008
23. Cao, Y., Rathmell, J. C., & Macintyre, A. N. Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells. PLoS ONE 9, e104104 (2014
24. Sumida, Y., Niki, E., Naito, Y., & Yoshikawa, T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic. Res. 47, 869-880 (2013
25. Porporato P. E., et al. A mitochondrial switch promotes tumor metastasis. Cell Reports 8, 754-766 (2014
26. Feldstein A. E., et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Lipid Res. 51, 3046-3054 (2010
27. Muir K., et al. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. Cancer Res. 73, 4722-4731 (2013
28. Beraza N., et al. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Gut 57, 655-663 (2008
29. Henao-Mejia J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179-185 (2012
30. Miura K., et al. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology 57, 577-589 (2013
31. Andersson J., et al. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-β-dependent manner. J. Exp. Med. 205, 1975-1981 (2008
32. Nakagawa H., et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 26, 331-343 (2014
33. Ikehara Y., et al. CD4+ Vα14 natural killer T cells are essential for acceptance of rat islet xenografts in mice. J. Clin. Invest. 105, 1761-1767 (2000
34. Hanczko R., et al. Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J. Clin. Invest. 119, 1546-1557 (2009
35. Radaeva S., et al. Interferon-α activates multiple STAT signals and downregulates c-Met in primary human hepatocytes. Gastroenterology 122, 1020-1034 (2002
36. Chen, R. F. Removal of fatty acids from serum albumin by charcoal treatment. J. Biol. Chem. 242, 173-181 (1967
37. Huynh, F. K., Green, M. F., Koves, T. R., & Hirschey, M. D. Measurement of fatty acid oxidation rates in animal tissues and cell lines. Methods Enzymol. 542, 391-405 (2014
38. Pelletier, M., Billingham, L. K., Ramaswamy, M., & Siegel, R. M. Extracellular flux analysis to monitor glycolytic rates and mitochondrial oxygen consumption. Methods Enzymol. 542, 125-149 (2014
39. Kleiner D. E., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005
40. Bedossa, P., & Poynard, T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24, 289-293 (1996
41. Hoechst B., et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells. Gastroenterology 135, 234-243 (2008